Connect with us

HealthNews

India releases MANAS 1: AI trained using 60,000 hours worth of brainwave recordings aims to detect disorders as early as possible


New Delhi : Artificial intelligence could soon help doctors “read the brain” before disease is visible. A team of Indian scientists has developed MANAS 1, the Brain Language Foundation Model based on recordings of over 25,000 brainwaves. This model is designed to enable earlier detection of neurological disorders and psychiatric disorders. The model, developed by Intellihealth, led by Dr Puneet agarwal (former Professor at All India Institutes of Medical Sciences) and his team and launched by Hugging Face during an AI Summit, was created by Intellihealth. The Indian AI Mission of Ministry of Electronics and Information Technology funded the project with computational resources. MANAS 1 has been trained, unlike other AI systems to interpret EEG (electrical activity) signals. The 400 million parameters it contains are described by its creators as a foundation platform for developing AI tools that target specific diseases. The MANAS 1 model, which is similar to ChatGPT in concept, was developed by Dr Agarwal to help “understand the language of the brain.” This foundation model learns to interpret brain signals from large-scale EEG datasets that can’t be fully decoded using traditional tests like MRI. He said that the model provides a foundation on which AI tools to treat epilepsy and dementia, as well as other disorders, can be later built. It also helps researchers understand aspects of brain function, which are still poorly understood. The public health argument revolves around early access. India is facing a neurology and psychiatrist shortage, especially outside of major cities. The brain disorders are detected late and can lead to increased disability as well as long-term costs. Developers say that tools developed on MANAS 1 can assist doctors in Ayushman Arogya Mandirs and community health centres, as well as district hospitals and district hospitals with preliminary screening and timely referral. Before clinical deployment, any AI model that is disease-specific and derived from this platform will need to be proved by regulatory agencies. If such systems are validated at a scale, they could help reduce gs between symptom onsets and diagnoses — an important factor in conditions such epilepsy or dementia. MANAS 2 is the next-generation system, and it’s expected to be released in the coming week. MANAS 1 is a first step in the advancement of artificial intelligence into neuroscience. It aims to translate the electrical language spoken by the brain to the screen. This will have implications for research and diagnosis, as well as access to healthcare.

Published on Feb 23, 2026, at 2:35 PM (IST)

Join our community of over 2 million industry professionals. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

You can now get all the information about ETHealthworld on your mobile!

Continue Reading

HealthNews

Medanta reports Rs1,195 crores in Q4 FY26; net profit jumps 40%.


New Delhi, Global Health Limited, which operates the corporate hospital network, Medanta, reported a 25.3% year-on year (YoY), increase in total income of Rs 1,195 crores for the quarter ending March this year. Ebitda for this period increased by 17.4% to Rs.290 crore and net profit jumped by 39.7% to reach Rs.141 crore as compared to the Rs.101 crore of Q4 FY25. Medanta has added 86 additional beds to its cacity in Q4 – 32 at Patna and 44 in Noida. The company’s average revenue per occupied beds (ARPOB) rose by 4.8 percent YoY to Rs. 66,687. The facility now has 382 beds with 98 ICU beds as well as 14 operating theatres.

The revenue from international patients was Rs. 67 crore, an increase by 22 per cent year-over-year, but a slight decline in the following months due to flight delays during the West Asia conflict. Bed occupancy was at 62.7%, and out-patients increased by 18.7%.


Published on May 15, 2026, at 2:41 PM (IST)

Join the community and join 2M+ other industry professionals. Subscribe to our Newsletter for the latest industry insights & analyses.

You can now get all the information about ETHealthworld on your mobile!

HealthNews

It is not the technology that will differentiate organisations, but rather superior decision-making. It’s the standard. Many large pharmaceutical companies and medical device manufacturers have already digitalised core functions. From CRM platforms to AI, these companies are far ahead of the curve. Prabha sinha, ZS Co-founder observes that the real shift is now not adding more technology, but rather using it more intelligently.


The ROI comes from the impact of digital on customers. “Digital can keep lights on like S, an infrastructure play,” said he. The real return on investment is when digital drives impact for customers.

This shift from infrastructure to impact is reshing the way life sciences organizations think, act and compete. Four engines of impact: From Projects to digital assets

Sinha described four “engines” that are driving the shift away from traditional projects and towards scalable digital impact. “One of the things that you can do with digital is to shift from project teams doing work, to digital assets doing work,” said Sinha.

Before, it could take up to an entire year for major business decisions such as restructuring the sales force in order to launch a new product. Ten years ago, it took six months to research and six more months to implement. The cycle lasted about a full year. Sinha noted. First, the decision-making cycle has been compressed significantly. “Decision-making can either be accelerated, or planning can be merged with execution,” he said. In place of quarterly planning cycles it is now done on the fly. “It’s a continuous rather than discrete process,” said he. First, digital tools help break down silos. Sinha explained that traditionally, in large companies the departments of sales, service and marketing were quite segregated. Now, digital is breaking down these vertical barriers. It was also important to him that centralised be used. He said: “All of this can only be achieved through centralising marketing and sales – the fourth component.” Sinha, who spoke about AI and for customer engagement, said that the top 100 pharmaceutical companies in the US are all doing it. The differences are in the sophistication. But “in terms of helping salespeople and marketers to determine how to allocate resources, this is a universal AI driven activity now.” Around 70% of ZS’s global workforce are based in India. Much of the intellectual properties behind ZAIDYN – the company’s AI-powered platform – is also developed here. Sinha noted that India was not only a cost center, but also a talent hub. Indian teams were increasingly client-facing, and the innovation process is centered in India. “Much innovation… Many of the algorithm programmes are developed in India.” Sinha said that there is a lack of automated bots being used by companies with customers and physicians. In almost all cases, a human is checking what is hpening. “So, I think that trust is best established through people right now.”

Not more technology, but better decisions will drive healthcare’s next le.

Healthcare data volumes continue to grow ridly – from consumer searches and physician queries to millions of sales interactions per year within a single large pharmaceutical company. Sinha explained that the value of understanding patterns between similar doctors, similar decision-makers, and similar hospitals will come through understanding. He claimed that better informational symmetry could reduce wasted products and improve alignment between product needs and patient requirements. Sinha stated, “Three year implementation cycles are not viable.” The technology is changing faster than the companies can implement it.

Platforms, such as ZAIDYN enable organisations to “be up-and-running within weeks, rather than years,” and to connect evolving tools, without having to rebuild their infrastructure with each new technological advancement. The Bottom Line

Healthcare’s next breakthrough will not be achieved by incrementally adopting technology, Sinha believes. “Competitive differentiating will come from superior intelligence in decision making, not just technology deployment,” said Sinha. The technology may provide the tools but the advantage will go to the organisations who transform data into smarter and faster decisions in the healthcare ecosystem.

Published On February 26, 2026 at 3:07 PM (IST)

Join our community of over 2 million industry professionals. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

You can now get all the information about ETHealthworld on your mobile!

Continue Reading

HealthNews

After 50 hearings in Daiichi Fortis case, the Delhi High Court reserves its judgement


New Delhi. Lawyers for Janese drugmaker and hospital chain Fortis Healthcare, FHL, concluded their arguments after 50 sessions. Daiichi seeks enforcement of an arbitral award it received against former Fortis Promoters Malvinder and Shivinder. The case involves alleged fraud committed in the 2008 sale to the Janese company of Ranbaxy Laboratories by the two promoters. The amount of money that was awarded by a Singore court a decade back has grown to Rs 5,200 crore, including interest.

Daiichi wanted the Singh brothers not to dilute their Fortis share, so they paid the money. But lenders used the pledged shares and sold them to recover debt. It has become a three way contest between Singh brothers, Fortis and lenders over who is responsible for the shrinking assets of Singh Brothers. Daiichi was represented by Arvind Subramanium and Giriraj Nigam, senior advocates, who questioned Fortis stake transactions including the sale 186 million shares that were encumbered, calling them deliberate asset destruction.

The nub of the issue is that there are two aspects to FHL’s transaction. One is the sale of unencumbered shares, and the second is the formation (with IHH taking control of the hospital network). They are two separate issues. Nigam told the Justice Subramonium Prasad bench that the dissipation occurred at a time when the Singh brothers controlled the entity. “There’s a regulatory framework that places obligations on a company’s compliance officer, and it puts promoters shares in the shadows. According to the Sebi regulatory framework, promoter shares couldn’t have been sold off without proval from the compliance officer. He said that “18.6 million (186 millions) shares were encumbered with disclosures made by financial institutions and bank-disclosures were uploaded by the company, and then sold. This left 13.99 crore unencumbered shares which were sold in transactions proved by the compliance officer, at a time when FHL was a judgment debtor. Fortis resisted Daiichi’s attempts to hold the company responsible for the dissipation the promoter stake. It argued that Daiichi had all the legal tools available to protect their interests and chose to ignore them for almost a decade. Fortis’s lawyer told the court: “I have been instructed to confirm that FHL, and its compliance officer, never gave proval to any transfer.”

Published on May 27, 2026, at 7:15 AM (IST)


Join the community and join 2M+ other industry professionals. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

Your smartphone is your portal to ETHealthworld!


HealthNews

AI will bring consistency in fertility care and precision based on data: Experts.


Mumbai. At the ETHealthworld Conclave for Fertility, a panel discussion on “Egg Meets Algorithm: The Next Frontier in Reproductive Health”, brought together embryologists, clinicians and genomics specialists to explore how artificial intelligence (AI), is reshing reproductive health care. Conversations highlighted a crucial shift from trial-and error IVF to a data-driven, personalized and predictive proach.

Dr Nikita lad Patel, ollo Fertility’s Consultant IVF specialist, started the conversation by explaining how AI has begun to detect patterns in embryos and gametes that were previously invisible to humans. By using advanced , clinicians are increasingly able refine embryo selection to improve outcomes and reduce the need for multiple IVF cycles. But she also noted that AI has “two sides”: while it is promising in terms of improving pregnancy chances, and clinical precision, the real-world plications are still evolving.

Dr Kshitiz murdia, co-founder and CEO of Indira iVF, provided a practical perspective. She noted that, while AI hasn’t yet improved pregnancy rates dramatically, it is having the most immediate impact on improving consistency and reducing variation in clinical practice in India. AI-powered clinical systems can help standardise the decision-making process across clinics, and among practitioners. He stressed that IVF generates a vast amount of data, from the demogrhics of patients and their hormonal profiles, to the embryo development and transfer methods. The next step in fertility care could be achieved by integrating this data and using AI-driven analysis. He explained that it’s not only about choosing the best embryos or marginal gains in the pregnancy rate. The real value is in providing consistent, high quality care across geogrhic regions and clinicians. Dr Murdia warned against relying too heavily on algorithms. Current AI tools are sometimes unable to correctly classify embryos in some cases, he said, particularly when complex cases are involved. This highlights the importance of a “human in the loop” proach where clinicians and embryologists remain at the center of decision-making. AI should be used as a tool to assist rather than replace them.

Expanding on the discussion of high-risk pregnancies Dr Sonal Kumta Senior Consultant Obstetrician, Fortis Hospital Mulund, stressed the importance of data-driven insight in managing patients who have a bad obstetric record, such as recurrent miscarriages or unexplained loss. She said that such cases are emotionally and clinically difficult due to the lack clear diagnostic answers. She believes AI can identify patterns, whether hormonal or genetic. This will allow for more accurate risk assessment and treatment plans. Data-backed insights, from decisions about interventions such as cervical cerclage to optimising the monitoring of foetals, can help provide greater clarity and assurance in managing these high stakes pregnancies. But she insisted that clinical knowledge is essential and AI can be used to support evidence-based medicine.

Another key area of focus was the role of AI in reproduction genetics. Shaiket Deb, Director of Rare Diseases and Reproductive Health at Strand Life Sciences, emphasized that many existing genetic classifications rely on Western datasets and are not plicable to Indians. Researchers are beginning to identify genetic variations that are specific to a population and their clinical significance. AI also accelerates the interpretation of genetic information, cutting turnaround times from weeks to a few short days. It helps clinicians to make better decisions faster by prioritising and filtering genetic data. Deb warned against testing without regard to the patient’s needs, pointing out that AI can be used to tailor testing strategies. The panel agreed that AI was not meant to replace human expertise, but rather as a powerful tool. Its true potential is to enhance clinical judgment, improve standardisation, and unlock insights from complex datasets, which were previously underutilised.

As the fertility care industry becomes more data-intensive, it is the intersection of biology with technology that will redefine reproductive medicine. The journey to integrate AI is in its beginning stages. However, it promises a future that is more accurate and personalized, as well as more accessible and equitable for diverse patient populations.

Published On March 31, 2026 at 06 :12 PM IST
Join the community and join 2M+ professionals in your industry. Subscribe to our Newsletter for the latest industry insights & analyses.

You can now get all the information about ETHealthworld on your mobile!


HealthNews

Surya Hospitals opens Kandivali hospital; adds 55 beds at Santacruz facility.


We have five children and women’s-only hospitals located in Mumbai, Jaipur and Pune. These will soon be operational. We plan to open a new facility this year in Kandivali and we’ve expanded our Santacruz location. The cex for these two hospitals is Rs 80 crores,” said Dr Bhupendra Avasthi, founder, chairman, and managing director of Surya Hospitals, to PTI. Surya Hospitals, Santacruz, has increased the number of beds in the Amber Wing by 55, bringing the total to over 250. The company, he added, is well-funded and will raise the funds through internal accruals. Surya Hospitals, according to Dr Avasthi, is also exploring the possibility of setting up a women’s and children’s speciality hospital in Ahmedabad.

We hope to have our Ahmedabad facility operational by the end of this fiscal. He added that it would take an additional year before the hospital was operational.

Published on May 16, 2026, at 6:48 AM (IST)

Join our community of over 2M industry professionals. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

You can now get all the information about ETHealthworld on your mobile!

Latest News

Video57 minutes ago

Audie Cornish reacts to Ari Shapiro getting a puppy

CNN's new podcast Engagement Party is for animal lovers and non-animal lovers alike Watch Audie Cornish and Ari Shapiro …

Video1 hour ago

New option for diagnosing a cancer that’s on the rise in young people

The American Cancer Society is adding some new testing options to its screening guideline for colorectal cancers – and for...

HealthNews1 hour ago

India releases MANAS 1: AI trained using 60,000 hours worth of brainwave recordings aims to detect disorders as early as possible

New Delhi : Artificial intelligence could soon help doctors “read the brain” before disease is visible. A team of Indian...

Video1 hour ago

Five people found alive after week trapped in flooded Laos cave. #Laos #BBCNews

Latest on Matthews, McDavid, Hughes and other big-name players Latest on Matthews, McDavid, Hughes and other big-name players
Sports1 hour ago

Latest on Matthews, McDavid, Hughes and other big-name players

As the NHL season nears a close, teams are gearing up for what could be a busy summer. A jump...

Trump’s primary scorecard for May: From the Politics Desk. Subscribe to this story to enjoy it ad free Trump’s primary scorecard for May: From the Politics Desk. Subscribe to this story to enjoy it ad free
BBC News World1 hour ago

Trump’s primary scorecard for May: From the Politics Desk. Subscribe to this story to enjoy it ad free

Enjoy unlimited access to exclusive content and ad free articles. From the Politics Desk We take a look at President...

Video2 hours ago

Trump: We're looking to renovate WWII Memorial fountain

During a White House Cabinet meeting Wednesday, President Trump suggested renovating Washington's World War II Memorial …

From gate to getaway: How Delta celebrated its newest European routes From gate to getaway: How Delta celebrated its newest European routes
TravelNews2 hours ago

From gate to getaway: How Delta celebrated its newest European routes

As Delta launches its largest-ever transatlantic schedule, destination-inspired celebrations and special onboard touches brought the airline’s newest European routes to...

Video2 hours ago

Russian cosmonauts spacewalk outside ISS

Two Roscosmos cosmonauts conducted a spacewalk outside the International Space Station. ISS Expedition 74 commander …

Bootids Meteor Shower May Explode With Meteors or Fizzle Out: How to Watch Bootids Meteor Shower May Explode With Meteors or Fizzle Out: How to Watch
Tech2 hours ago

Bootids Meteor Shower May Explode With Meteors or Fizzle Out: How to Watch

There are still tons of mysteries in the universe, and the Bootids meteor shower is one of them. The upcoming...

Trending News

Join Our Newsletter

Stay updated with breaking news and exclusive content.